The market expects CVRx (CVRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is ...

William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on CVRx (CVRX – Research Report). The company’s ...

Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35%Full year revenue expected to ...

CVRx anticipates a 35% increase in Q4 2024 revenue and a 30% increase in FY24 revenue, with shares down 1.55% premarket.

MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43 rd ...

NASDAQ:CVRX opened at $13.64 on Monday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 10.23 and a current ratio of 11.32. The company has a market capitalization of $330.91 ...

William Blair analyst Margaret Kaczor upgraded CVRx (CVRX) to Outperform from Market Perform.Stay Ahead of the Market:Discover outperforming ...

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. About CVRx, Inc. CVRx is focused on ...

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, Inc. CVRx is focused on the ...